Prescribing proton-pump inhibitors to irritable infants: Where is the evidence?

Pediatric Health

Volumn 3, Issue 3, 2009, Pages 213-215

  Gunasekaran, Thirumazhisai S ^a   Singla, Shikha ^b   Dahlberg, Mary ^b  

^a Division of Pediatric Gastroenterology and Nutrition   (United States)

^b Center for Children's Digestive Health   (United States)

Author keywords

Acid reflux; Efficacy; Evidence base; Gastroesophageal reflux disease; GERD; Infant; Irritable infant; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABILITY; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 70349636731     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/phe.09.18     Document Type: Article

References (15)

1. Vandenplas Y, Badriul H, Verghote M, Hauser B, Kaufman L: Oesophageal pH monitoring and reflux oesophagitis in irritable infants. Eur. J. Pediatr. 163, 300-304 (2004).
2. Moore DJ, Tao BS, Lines DR et al.: Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J. Pediatr. 143, 219-223 (2003).
3. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M: Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J. Pediatr. 154, 514-520 (2009).
4. Springer M, Atkinson S, North J, Raanan M: Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Paediatr. Drugs 10, 255-263 (2008).
5. Tran A, Rey E, Pons G et al.: Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin. Pharmacol. Ther. 71, 359-367 (2002).
6. Andersson T, Anderson G, Dasen S et al.: Pharmacokinetics and pharmacodynamics of oral omeprazole in infants. J. Pediatr. Gastroenterol. Nutr. 33, 416-425 (2001).
7. Omari T, Davidson G, Bondarov P et al.: Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gatroesophageal reflux disease. J. Pediatr. Gatroenterol. Nutr. 45, 530-537 (2007).
8. Ginsberg G, Hattis D, Miller R, Sonawane B: Pediatric pharmacokinetic data: implications for environmental risk assessment for children. Pediatrics 113, 973-983 (2004).
9. Canani RB, Cirillo P, Roggero P et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5), e817-e820 (2006).
10. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947-2953 (2006).
11. Dial S, Delaney JAC, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294, 2989-2995 (2005).
12. Buckley RH: T lymphocytes, B lymphocytes and natural killer cells. In: Nelson Textbook of Pediatrics 18th Edition. Kliegman RM, Jenson HL, Behrman RE, Stanton BF (Eds). Saunders Elsevier, Philadelphia, PA, USA, 873-879 (2007).
13. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J: Proton pump inhibitor utilization pattern in infants. J. Pediatr. Gastroenterol. Nutr. 45, 421-427 (2007).
14. Orenstein SR, Hassall E: Infants and proton pump inhibitors: tribulations, no trials. J. Pediatr. Gastroenterol. Nutr. 45, 395-398 (2007).
15. Diaz DM, Winter HS, Colletti RB et al.: Knowledge, attitudes and practice styles of North American pediatricians. J. Pediatr. Gastroenterol. Nutr. 45, 56-64 (2007).